Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Post by Bradwaiton Mar 03, 2021 7:13am
223 Views
Post# 32702679

The Good and the Bad

The Good and the Bad

Some will see this pp before results as an indication results are not good. However its not likely the company knows the results until this Friday. So therefore the pp is prudent and not large considering the massive upside potential here.

There are other examples of repurposed drugs that have gone on to be blockbusters in their new indications. Most of you know blockbuster refers to a drug with sales in excess of $1 Billion annually. So next to this type of upside a $2.7 million raise from just over 10 million shares is not a big deal at all. Don't forget we also raised a few million recently with the exercise of outstanding warrants . The company has some cash and that is not a negative.

From Aug.12, 2020 news release:

the Company is betting that this quiet and unassuming safe generic drug may soon become a global blockbuster. The Company is claiming it has filed new patents globally for Ifenprodil for the treatment of respiratory diseases. Algernon has advised that they are following the same re-purposed drug business model as Biogen with their re-purposed drug Tecfidera and Celgene’s Thalidomide, both billion dollar blockbuster drugs in their own right.

I googled Tecfidera and found they did over $1 billion in sales from a single quarter. Yes in just 3 months thats what a repurposed drug did in sales.

Hello is anyone awake out there? We are in the largest medical crisis of our lifetimes and here this little penny stock may well have a repurposed drug that kicks butt where it needs to be kicked. If so, this has blockbuster written all over it. Massive upside potential from this tiny cap we are starting with.

We will know a lot more next week. Don't forget the two videos regarding the phase 2 trial which both sound extremely positive.


 

<< Previous
Bullboard Posts
Next >>